Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > A bunch of SHOBS
View:
Post by mercedesman on Sep 13, 2023 1:06pm

A bunch of SHOBS

I see the SHOBS are still at it (sewing FUD).  Usually a good sign/time to accumulate.

SHOBS? You know the "investors" who to a man, are out of Spectral but feel compelled to bash it at every turn (despte a 60% increase in price over the past 3 months).  Some couch it as "I'm 90% out" but just want to watch the ship go down.


SHOBS?

Stuckupatree
Hummmmmmmmmer
Oil&Gasbag
BSWild&getting wilder
Spamguy

FUD?

Fear Uncertainty and Doubt.

Actually it's one guy....tasked with keeping new investors away...and to keep the SP gains muted.

Harder and harder to do as the 90 patient interim Review date approaches.  So give (him) them their (his) due...he (they) has (have) been able to hold it to just a 60% gain of late, and likely 1/4 to 1/3 of its true pre-FDA trading value.

Agree with AP....the harder he(they) work(s), the more that smart money can accumulate on sale before the denouement in H1 2024.

glta

MM
Comment by mercedesman on Sep 13, 2023 1:15pm
Correction: 58.3% gain on the 3 month chart 
Comment by Accountprince on Sep 13, 2023 1:40pm
Thanks MM.  Unfortunately these (this) SHOBS are not that good.  After asking them (him) for help to bash down the share price into the 20's or very low 30's it's barely moved.  Even worse, they seem to be talking absurdly about other things and not even doing a direct bash.  One even claims to know the whereabouts, movements and major personal expenditures of all ...more  
Comment by Geery on Sep 13, 2023 1:52pm
The 'Shobs' are working overtime because everybody responds to them. Ignore them or put them on ignore. Keep giving them ammo and they will keep commenting.
Comment by mercedesman on Sep 13, 2023 1:52pm
Not to worry AP It's like we're getting paid twice anyway when the bashers (SHOBS) knocked it down to the twenties from the fifties (when BSWild was born) Sell high, buy low...repeat. MM PS  Give me your thoughts on the new deck.  Tigris and Euphas2 seem to be all but guarantteeing us a positive FDA outcome - would you not agree? I like a good de-risked biotech, myself.
Comment by Accountprince on Sep 13, 2023 2:11pm
I would like to pick up another 5% or so to add and that way no dilution to my position for the recent raise.  But it looks like the inadequate SHOBS won't move the needle anywhere close to a decent purchase price.  Glad I have the position I have accumulated. I like to buy low.  I will sell high but won't take a chance by trading this one now.  Even if it was $0.50 or ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities